1. Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum.
- Author
-
Smeaton, Laura M, Kileel, Emma M, Grinsztejn, Beatriz, Gardner, Edward M, Starr, Kate, Murry, Melissa L, Desvigne-Nickens, Patrice, Alston-Smith, Beverly, Waclawiw, Myron A, Cooper-Arnold, Katharine, Madruga, José V, Sangle, Shashi, Fitch, Kathleen V, Zanni, Markella V, Douglas, Pamela S, Ribaudo, Heather J, Grinspoon, Steven K, and Klingman, Karin L
- Subjects
POPULATION ,GENDER identity ,WAIST circumference ,HIV ,MEDICAL care - Abstract
Because persons who identify across the transgender spectrum (PATS) are a key population in human immunodeficiency virus (HIV) yet are underreported in HIV and cardiovascular research, we aimed to characterize this population within the REPRIEVE global clinical trial (n = 7770). Acceptance of gathering gender identity was high (96%). Participation by PATS was 1.7% overall, 2.4% among natal males, 0.3% among natal females, and varied across geographic regions (from 0% in sub-Saharan Africa to 2.3% in High Income Region). Thirty percent of natal male PATS identified other than transgender. Some characteristics differed by gender. Most notably, 38% of natal male PATS receiving gender-affirming treatment had waist circumference >102 cm (compared with ≤25% in other groups). Given that PATS is a key population, HIV research should routinely report trial participation and outcomes by gender in addition to natal sex, to provide the results needed to optimize medical care to PATS. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF